Krystal Biotech downgraded by Citigroup with a new price target

8/6/24 8:53:09 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Citigroup downgraded Krystal Biotech from Buy to Neutral and set a new price target of $204.00 from $195.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KRYS

Date	Price Target	Rating	Analyst
3/5/2025	$245.00	Buy	Jefferies
8/6/2024	$195.00 → $204.00	Buy → Neutral	Citigroup
11/20/2023	$160.00	Buy	Goldman
10/24/2023	$100.00	Overweight	Cantor Fitzgerald
10/12/2023	$160.00	Buy	Citigroup
9/7/2023	$154.00	Buy	Berenberg
4/18/2023	$102.00	Buy	Stifel
2/28/2023	$79.00 → $124.00	Neutral → Buy	Goldman